<DOC>
	<DOCNO>NCT02461134</DOCNO>
	<brief_summary>Chronic graft versus host diseasre ( GVHD ) serious reaction might occur person ( host ) receive cell organ ( graft ) another person graft attack host 's cell . Currently approve therapy chronic GVHD USA , patient chroninc GVHD treat immunosuppressant drug . T-lymphocytes ( type white blood cell ) likely play role development chronic GVHD . Due capacity ponesimod block traffic T-lymphocytes , ponesimod may new therapeutic approach treat chroninc GVHD . The main objective study ass effectiveness safety several dos ponesimod subject chronic GVHD respond standard available treatment .</brief_summary>
	<brief_title>Clinical Study Investigate Biological Activity , Safety , Tolerability , Pharmacokinetics Ponesimod Subjects With Symptomatic Chronic GVHD</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Signed informed consent Symptomatic moderate severe chronic GVHD patient need change systemic immunosuppressant ( IS ) therapy Women child bear potential must negative pregnancy test use reliable method contraception Clinically significant medical condition include active uncontrolled infection , new recurrent malignancy , serious cardiac , pulmonary , renal disease , uncontrolled diabetes . Karnofsky Performance Score &lt; 60 . Immunosuppressant therapy allow background therapy Antiarrhythmic heart rate lower drug . Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>GVHD</keyword>
	<keyword>ponesimod</keyword>
</DOC>